Your browser is no longer supported. Please, upgrade your browser.
ATHE [NASD]
Alterity Therapeutics Limited
Index- P/E- EPS (ttm)-0.44 Insider Own18.70% Shs Outstand34.51M Perf Week-2.99%
Market Cap56.47M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float20.81M Perf Month-0.76%
Income-11.40M PEG- EPS next Q- Inst Own2.50% Short Float3.56% Perf Quarter0.00%
Sales0.03M P/S2005.90 EPS this Y40.00% Inst Trans- Short Ratio0.50 Perf Half Y-13.91%
Book/sh0.66 P/B1.97 EPS next Y- ROA-64.20% Target Price4.00 Perf Year-17.20%
Cash/sh- P/C- EPS next 5Y- ROE-73.60% 52W Range1.09 - 3.58 Perf YTD-2.99%
Dividend- P/FCF- EPS past 5Y9.00% ROI- 52W High-65.78% Beta1.53
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low12.39% ATR0.05
Employees11 Current Ratio10.90 Sales Q/Q1.50% Oper. Margin- RSI (14)40.57 Volatility5.43% 3.67%
OptionableNo Debt/Eq0.00 EPS Q/Q67.80% Profit Margin- Rel Volume1.11 Prev Close1.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.49M Price1.23
Recom- SMA20-5.11% SMA50-6.53% SMA200-16.00% Volume1,379,211 Change-5.77%
Oct-19-21 05:08PM  
Sep-20-21 10:51AM  
Aug-04-21 08:39AM  
Jul-30-21 09:05AM  
Jul-15-21 09:52AM  
Jul-01-21 11:51AM  
07:50AM  
Jun-23-21 09:21AM  
Jun-07-21 11:04AM  
Apr-29-21 08:30AM  
Apr-21-21 09:25AM  
08:11AM  
Feb-26-21 07:45AM  
Feb-09-21 08:53AM  
Jan-07-21 08:00AM  
Dec-21-20 08:30AM  
Dec-09-20 09:46AM  
Nov-16-20 10:42AM  
08:42AM  
Oct-26-20 10:03PM  
Aug-05-20 03:10PM  
Aug-04-20 09:07AM  
02:33AM  
Aug-03-20 09:33PM  
Jul-30-20 06:49PM  
Jul-01-20 08:12AM  
Jun-29-20 11:14PM  
May-20-20 08:58PM  
Apr-30-20 04:35AM  
Apr-21-20 05:50PM  
Feb-21-20 07:15PM  
Nov-11-19 10:30PM  
Sep-12-19 11:07PM  
Jul-29-19 08:00AM  
Jul-11-19 09:31PM  
May-06-19 08:00AM  
May-03-19 08:00AM  
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.